Safety of tralokinumab in patients with moderate-to-severe atopic dermatitis followed for up to 4.5 years: an integrated analysis of eight clinical trials.
- DOI
- 10.1093/bjd/ljaf309
- Published
- 2026-01-01
- Container
- Br J Dermatol
- Publisher
- Not recorded
- Open access
- no
Credibility signals
limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1093/bjd/ljaf309,
title = {Safety of tralokinumab in patients with moderate-to-severe atopic dermatitis followed for up to 4.5 years: an integrated analysis of eight clinical trials.},
author = {Reich K and Langley RG and Silvestre Salvador JF and Staumont-Sallé D and Costanzo A and Pink AE and Paller AS and Katoh N and Wollenberg A and Warren RB and Blauvelt A and Bjerregård Øland C and Tindberg AM and Gjerum L and Simpson EL.},
year = {2026},
journal = {Br J Dermatol},
doi = {10.1093/bjd/ljaf309},
url = {https://doi.org/10.1093/bjd/ljaf309}
}RIS
TY - JOUR TI - Safety of tralokinumab in patients with moderate-to-severe atopic dermatitis followed for up to 4.5 years: an integrated analysis of eight clinical trials. AU - Reich K AU - Langley RG AU - Silvestre Salvador JF AU - Staumont-Sallé D AU - Costanzo A AU - Pink AE AU - Paller AS AU - Katoh N AU - Wollenberg A AU - Warren RB AU - Blauvelt A AU - Bjerregård Øland C AU - Tindberg AM AU - Gjerum L AU - Simpson EL. PY - 2026 JO - Br J Dermatol DO - 10.1093/bjd/ljaf309 UR - https://doi.org/10.1093/bjd/ljaf309 ER -
APA
K, R., RG, L., JF, S. S., D, S., A, C., AE, P., AS, P., N, K., A, W., RB, W., A, B., C, B. Ø., AM, T., L, G., & EL., S. (2026). Safety of tralokinumab in patients with moderate-to-severe atopic dermatitis followed for up to 4.5 years: an integrated analysis of eight clinical trials.. Br J Dermatol. https://doi.org/10.1093/bjd/ljaf309
Source records
- europe-pmc · retrieved 2026-09-26T19:34:44.772Z
- hal · retrieved 2026-09-26T19:34:44.805Z